• Je něco špatně v tomto záznamu ?

Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism

PJ. Marchena, I. Tzoran, B. Brenner, M. Martín, R. Malý, A. Bura-Riviere, R. Valle, L. Hernández-Blasco, JB. López-Sáez, M. Monreal, RIETE Investigators,

. 2020 ; 120 (4) : 620-626. [pub] 20200414

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028343

BACKGROUND:  The influence (if any) of the use of psychotropic drugs on outcome in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated. METHODS:  We used data from the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the risk for VTE recurrences, major bleeding, or death during the course of anticoagulant therapy, according to the use of psychotropics at baseline. RESULTS:  Among 49,007 patients with VTE enrolled from February 2009 to September 2019, total 5,230 (11%) were using psychotropics at baseline: antidepressants 3,273 (6.7%), antipsychotics 1,588 (3.2%), and anticholinesterases 369 (0.7%). During the course of anticoagulation, 1,259 patients developed VTE recurrences, 1,231 bled, and 3,988 died (fatal pulmonary embolism 269 and fatal bleeding 187). On multivariable analysis, patients using psychotropics at baseline had a similar risk for VTE recurrences (adjusted hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.58-1.12), a nonsignificantly higher risk for major bleeding (adjusted HR: 1.15; 95% CI: 0.97-1.35), and a higher risk for intracranial bleeding (adjusted HR: 1.83; 95% CI: 1.32-2.53) or death (adjusted HR: 1.44; 95% CI: 1.32-1.57) compared with those not using psychotropics. When separately analyzed, the highest risk for intracranial bleeding was found in patients using antidepressants (adjusted HR: 1.60; 95% CI: 1.08-2.37) or antipsychotics (adjusted HR: 2.02; 95% CI: 1.17-3.49) but not in those on anticholinesterases (adjusted HR: 1.69; 95% CI: 0.62-4.60). CONCLUSION:  During the course anticoagulation for VTE, patients using psychotropics at baseline were at increased risk for intracranial bleeding.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028343
003      
CZ-PrNML
005      
20210114153558.0
007      
ta
008      
210105s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0040-1708482 $2 doi
035    __
$a (PubMed)32289861
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Marchena, Pablo Javier $u Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain.
245    10
$a Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism / $c PJ. Marchena, I. Tzoran, B. Brenner, M. Martín, R. Malý, A. Bura-Riviere, R. Valle, L. Hernández-Blasco, JB. López-Sáez, M. Monreal, RIETE Investigators,
520    9_
$a BACKGROUND:  The influence (if any) of the use of psychotropic drugs on outcome in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated. METHODS:  We used data from the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the risk for VTE recurrences, major bleeding, or death during the course of anticoagulant therapy, according to the use of psychotropics at baseline. RESULTS:  Among 49,007 patients with VTE enrolled from February 2009 to September 2019, total 5,230 (11%) were using psychotropics at baseline: antidepressants 3,273 (6.7%), antipsychotics 1,588 (3.2%), and anticholinesterases 369 (0.7%). During the course of anticoagulation, 1,259 patients developed VTE recurrences, 1,231 bled, and 3,988 died (fatal pulmonary embolism 269 and fatal bleeding 187). On multivariable analysis, patients using psychotropics at baseline had a similar risk for VTE recurrences (adjusted hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.58-1.12), a nonsignificantly higher risk for major bleeding (adjusted HR: 1.15; 95% CI: 0.97-1.35), and a higher risk for intracranial bleeding (adjusted HR: 1.83; 95% CI: 1.32-2.53) or death (adjusted HR: 1.44; 95% CI: 1.32-1.57) compared with those not using psychotropics. When separately analyzed, the highest risk for intracranial bleeding was found in patients using antidepressants (adjusted HR: 1.60; 95% CI: 1.08-2.37) or antipsychotics (adjusted HR: 2.02; 95% CI: 1.17-3.49) but not in those on anticholinesterases (adjusted HR: 1.69; 95% CI: 0.62-4.60). CONCLUSION:  During the course anticoagulation for VTE, patients using psychotropics at baseline were at increased risk for intracranial bleeding.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a databáze faktografické $7 D016208
650    12
$a lékové interakce $7 D004347
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x farmakoterapie $x epidemiologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a psychotropní léky $x terapeutické užití $7 D011619
650    _2
$a riziko $7 D012306
650    _2
$a výsledek terapie $7 D016896
650    _2
$a žilní tromboembolie $x farmakoterapie $x epidemiologie $7 D054556
651    _2
$a Španělsko $x epidemiologie $7 D013030
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tzoran, Inna $u Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
700    1_
$a Brenner, Benjamin $u Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
700    1_
$a Martín, Mar $u Department of Internal Medicine, Hospital Universitario Infanta Sofía, Madrid, Spain.
700    1_
$a Malý, Radovan $u Department of Cardiovascular Medicine I, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Bura-Riviere, Alessandra $u Department of Vascular Medicine, Hôpital de Rangueil, Toulouse, France.
700    1_
$a Valle, Reina $u Department of Internal Medicine, Hospital Sierrallana, Santander, Spain.
700    1_
$a Hernández-Blasco, Luis $u Department of Pneumonology, Hospital General Universitario de Alicante, ISABIAL, Alicante, Spain.
700    1_
$a López-Sáez, Juan Bosco $u Department of Internal Medicine, Hospital Universitario de Puerto Real, Cádiz, Spain.
700    1_
$a Monreal, Manuel $u Department of Internal Medicine, Hospital Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, Spain.
710    2_
$a RIETE Investigators
773    0_
$w MED00004517 $t Thrombosis and haemostasis $x 2567-689X $g Roč. 120, č. 4 (2020), s. 620-626
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32289861 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153555 $b ABA008
999    __
$a ok $b bmc $g 1608678 $s 1119523
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 120 $c 4 $d 620-626 $e 20200414 $i 2567-689X $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace